Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.

Michael Friedländer, Éric Pujade-Lauraine, Emma Gibbs et al.|Journal of Clinical Oncology|2017

Cited by 18